Understanding genetic risk factors for common side effects of antidepressant medications

Author:

Campos Adrian I.ORCID,Mulcahy Aoibhe,Thorp Jackson G.,Wray Naomi R.ORCID,Byrne Enda M.,Lind Penelope A.,Medland Sarah E.ORCID,Martin Nicholas G.ORCID,Hickie Ian B.,Rentería Miguel E.ORCID

Abstract

Abstract Background Major depression is one of the most disabling health conditions internationally. In recent years, new generation antidepressant medicines have become very widely prescribed. While these medicines are efficacious, side effects are common and frequently result in discontinuation of treatment. Compared with specific pharmacological properties of the different medications, the relevance of individual vulnerability is understudied. Methods We used data from the Australian Genetics of Depression Study to gain insights into the aetiology and genetic risk factors to antidepressant side effects. To this end, we employed structural equation modelling, polygenic risk scoring and regressions. Results Here we show that participants reporting a specific side effect for one antidepressant are more likely to report the same side effect for other antidepressants, suggesting the presence of shared individual or pharmacological factors. Polygenic risk scores (PRS) for depression associated with side effects that overlapped with depressive symptoms, including suicidality and anxiety. Body Mass Index PRS are strongly associated with weight gain from all medications. PRS for headaches are associated with headaches from sertraline. Insomnia PRS show some evidence of predicting insomnia from amitriptyline and escitalopram. Conclusions Our results suggest a set of common factors underlying the risk for antidepressant side effects. These factors seem to be partly explained by genetic liability related to depression severity and the nature of the side effect. Future studies on the genetic aetiology of side effects will enable insights into their underlying mechanisms and the possibility of risk stratification and prophylaxis strategies.

Publisher

Springer Science and Business Media LLC

Reference54 articles.

1. World Health Organization. The Global Burden of Disease: 2004 Update (World Health Organization, 2008).

2. Papakostas, G. I. Serotonin norepinephrine reuptake inhibitors: spectrum of efficacy in major depressive disorder. Primary Psychiatry 16, 16–24 (2009).

3. Cipriani, A. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet 391, 1357–1366 (2018).

4. Sansone, R. A. & Sansone, L. A. Antidepressant adherence: are patients taking their medications? Innovations Clini. Neurosci. 9, 41–46 (2012).

5. Rosen, R. C., Lane, R. M. & Menza, M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol. 19, 67–85 (1999).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3